No pipeline data
No cash flow data
Historical delivery and spending consistency. Data is limited for recently added companies.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
| Event | Type | Confidence | Impact | Date | Status |
|---|
| HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27open_in_new | commercial milestone | Confirmed | removeMed | 16 July 2026 | Completed |
| Neurizon executes long-term supply agreement with Elancoopen_in_new Neurizon executed a long-term five-year supply agreement with Elanco Animal Health for exclusive GMP-grade monepantel (the active pharmaceutical ingredient in NUZ-001) to support clinical, regulatory, and future commercialisation activities. | partnership | Confirmed | removeMed | 16 June 2026 | Completed |
| HEALEY ALS Trial Regimen I - Topline Resultsopen_in_new The HEALEY ALS Platform Trial surpassed the 50% dosing milestone with 129 of 240 participants dosed in Regimen I, ahead of schedule, demonstrating strong operational efficiency and recruitment momentum. | data readout | Expected | arrow_upwardHigh | 11 June 2026 | Completed |
| HEALEY ALS Trial Regimen I Expands to 240 Participantsopen_in_new Neurizon expands HEALEY ALS Platform Trial Regimen I from 160 to 240 participants to strengthen statistical robustness and biomarker analysis, driven by enrolment exceeding expectations. Trial timeline accelerated with last participant dosing expected Q2 2027 and topline results early Q3 2027, with no additional cost impact through topline due to philanthropic funding contribution from Mass General Brigham. | other | Confirmed | removeMed | 26 May 2026 | Completed |
| NUZ-001 Bellberry Human Research Ethics Committee (HREC) — Ethics Approval Received for NUZ-001 Oral Liquid P1 Studyopen_in_new The Bellberry Human Research Ethics Committee (HREC) approved Neurizon's Phase 1 formulation study for NUZ-001 oral liquid formulation in Australia. The study will enrol 32 healthy volunteers to generate pharmacokinetic, safety and tolerability data supporting clinical and regulatory development of NUZ-001 for ALS. | regulatory decision | Confirmed | removeMed | 12 May 2026 | Completed |